Characterisation of distinct subgroups of BRCA1-like triple-negative breast cancers with multiomics data analysis

被引：0
|
作者：
Chan, T. W. S. [1 ]
Opdam, M. [1 ]
Schouten, P. [1 ]
De Boo, L. [1 ]
Hilbers, F. S. [1 ]
Linn, S. C. [1 ]
De Menezes, R. X. [2 ]
机构：
[1] Netherlands Canc Inst, Dept Mol Oncol, Amsterdam, Netherlands
[2] Netherlands Canc Inst, Biostat Facil, Amsterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
基金：
欧盟第七框架计划;
关键词：
D O I：
10.1016/j.annonc.2022.07.151
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
119P
引用
收藏
页码：S592 / S593
页数：2
相关论文
共 50 条
  • [1] BRCA1-like signature in triple negative breast cancers within the RATHER (Rational Therapy for Breast Cancer) Consortium
    Severson, Tesa
    Peeters, Justine
    Majewski, Ian
    Bosma, Astrid
    Chin, Suet-Feung
    Caldas, Carlos
    Simon, Iris
    Bernards, Rene
    Linn, Sabine
    [J]. CANCER RESEARCH, 2013, 73 (08)
  • [2] BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential
    Severson, Tesa M.
    Peeters, Justine
    Majewski, Ian
    Michaut, Magali
    Bosma, Astrid
    Schouten, Philip C.
    Chin, Suet-Feung
    Pereira, Bernard
    Goldgraben, Mae A.
    Bismeijer, Tycho
    Kluin, Roelof J. C.
    Muris, Jettie J. F.
    Jirstrom, Karin
    Kerkhoven, Ron M.
    Wessels, Lodewyk
    Caldas, Carlos
    Bernards, Rene
    Simon, Iris M.
    Linn, Sabine
    [J]. MOLECULAR ONCOLOGY, 2015, 9 (08) : 1528 - 1538
  • [3] Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study
    Eva Gross
    Harm van Tinteren
    Zhou Li
    Sandra Raab
    Christina Meul
    Stefanie Avril
    Nadja Laddach
    Michaela Aubele
    Corinna Propping
    Apostolos Gkazepis
    Manfred Schmitt
    Alfons Meindl
    Petra M. Nederlof
    Marion Kiechle
    Esther H. Lips
    [J]. BMC Cancer, 16
  • [4] Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study
    Gross, Eva
    van Tinteren, Harm
    Li, Zhou
    Raab, Sandra
    Meul, Christina
    Avril, Stefanie
    Laddach, Nadja
    Aubele, Michaela
    Propping, Corinna
    Gkazepis, Apostolos
    Schmitt, Manfred
    Meindl, Alfons
    Nederlof, Petra M.
    Kiechle, Marion
    Lips, Esther H.
    [J]. BMC CANCER, 2016, 16
  • [5] BRCA1a has antitumor activity in triple-negative breast cancers
    Yuli, C.
    Shao, N.
    Oprea-Ilies, G.
    Okoli, J.
    Reddy, E. S. P.
    Rao, V. N.
    [J]. BREAST CANCER RESEARCH, 2007, 9 (01)
  • [6] BRCA1a has antitumor activity in triple-negative breast cancers
    C Yuli
    N Shao
    G Oprea-llies
    J Okoli
    ESP Reddy
    VN Rao
    [J]. Breast Cancer Research, 9
  • [7] A BRCA1-Like, 25-Gene Assay Predicts for Anthracycline-Chemosensitivity in Sporadic Triple-Negative Breast Cancer.
    Rodriguez, A. A.
    Rimawi, M.
    Wu, M-F
    Dave, B.
    Wong, H.
    Landis, M.
    Cairo, M.
    Pavlick, A.
    Froehlich, A.
    Chamness, G.
    Hilsenbeck, S. G.
    Lewis, M. T.
    Osborne, C. K.
    Chang, J.
    [J]. CANCER RESEARCH, 2009, 69 (24) : 509S - 509S
  • [8] NGS-Based Mutation Analysis of BRCA1-Associated Triple-Negative Breast Cancers
    Honisch, Ellen
    Froehlich, Rose
    Vesper, Anne-Sophie
    Beyer, Ines
    Fehm, Tanja
    Niederacher, Dieter
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 197 - 197
  • [9] PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers
    Stebbing, Justin
    Ellis, Paul
    Tutt, Andrew
    [J]. FUTURE ONCOLOGY, 2010, 6 (04) : 485 - 486
  • [10] Early stage cost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapy
    Miquel-Cases, Anna
    Steuten, Lotte M. G.
    Retel, Valesca P.
    van Harten, Wim H.
    [J]. BREAST, 2015, 24 (04): : 397 - 405
12345